208 related articles for article (PubMed ID: 24254641)
1. Capillary electrophoresis of urinary prostate glycoproteins assists in the diagnosis of prostate cancer.
Vermassen T; Van Praet C; Vanderschaeghe D; Maenhout T; Lumen N; Callewaert N; Hoebeke P; Van Belle S; Rottey S; Delanghe J
Electrophoresis; 2014 Apr; 35(7):1017-24. PubMed ID: 24254641
[TBL] [Abstract][Full Text] [Related]
2. Urinary prostate protein glycosylation profiling as a diagnostic biomarker for prostate cancer.
Vermassen T; Van Praet C; Lumen N; Decaestecker K; Vanderschaeghe D; Callewaert N; Villeirs G; Hoebeke P; Van Belle S; Rottey S; Delanghe J
Prostate; 2015 Feb; 75(3):314-22. PubMed ID: 25358590
[TBL] [Abstract][Full Text] [Related]
3. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
[TBL] [Abstract][Full Text] [Related]
4. Different glycan structures in prostate-specific antigen from prostate cancer sera in relation to seminal plasma PSA.
Tabarés G; Radcliffe CM; Barrabés S; Ramírez M; Aleixandre RN; Hoesel W; Dwek RA; Rudd PM; Peracaula R; de Llorens R
Glycobiology; 2006 Feb; 16(2):132-45. PubMed ID: 16177264
[TBL] [Abstract][Full Text] [Related]
5. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.
Salido-Guadarrama AI; Morales-Montor JG; Rangel-Escareño C; Langley E; Peralta-Zaragoza O; Cruz Colin JL; Rodriguez-Dorantes M
Mol Med Rep; 2016 Jun; 13(6):4549-60. PubMed ID: 27081843
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic potential in prostate cancer of a panel of urinary molecular tumor markers.
Talesa VN; Antognelli C; Del Buono C; Stracci F; Serva MR; Cottini E; Mearini E
Cancer Biomark; 2009; 5(6):241-51. PubMed ID: 20037200
[TBL] [Abstract][Full Text] [Related]
7. Prostate specific antigen density for discriminating prostate cancer from benign prostatic hyperplasia in the gray zone of prostate-specific antigen.
Uno H; Koide T; Kuriyama M; Ban Y; Deguchi T; Kawada Y
Hinyokika Kiyo; 1999 Jul; 45(7):457-61. PubMed ID: 10466060
[TBL] [Abstract][Full Text] [Related]
8. Release of urinary extracellular vesicles in prostate cancer is associated with altered urinary N-glycosylation profile.
Vermassen T; D'Herde K; Jacobus D; Van Praet C; Poelaert F; Lumen N; Callewaert N; Decaestecker K; Villeirs G; Hoebeke P; Van Belle S; Rottey S; Delanghe J
J Clin Pathol; 2017 Oct; 70(10):838-846. PubMed ID: 28360190
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic accuracy of urinary prostate protein glycosylation profiling in prostatitis diagnosis.
Vermassen T; Van Praet C; Poelaert F; Lumen N; Decaestecker K; Hoebeke P; Van Belle S; Rottey S; Delanghe J
Biochem Med (Zagreb); 2015; 25(3):439-49. PubMed ID: 26526330
[TBL] [Abstract][Full Text] [Related]
10. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
[TBL] [Abstract][Full Text] [Related]
11. [Changes of serum total PSA and free PSA in patients with prostate carcinoma and benign prostate hyperplasia].
Gao ZW; Liu G; Sheng BW
Ai Zheng; 2004 Jun; 23(6):701-3. PubMed ID: 15191675
[TBL] [Abstract][Full Text] [Related]
12. Glycosylation of prostate specific antigen and its potential diagnostic applications.
Vermassen T; Speeckaert MM; Lumen N; Rottey S; Delanghe JR
Clin Chim Acta; 2012 Oct; 413(19-20):1500-5. PubMed ID: 22722018
[TBL] [Abstract][Full Text] [Related]
13. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H
J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
[TBL] [Abstract][Full Text] [Related]
14. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
Hillenbrand M; Bastian M; Steiner M; Zingler C; Müller M; Wolff JM; Seiter H; Schuff-Werner P
Anticancer Res; 2000; 20(6D):4995-6. PubMed ID: 11326656
[TBL] [Abstract][Full Text] [Related]
15. Development of an ELISA for sPSP94 and utility of the sPSP94/sPSA ratio as a diagnostic indicator to differentiate between benign prostatic hyperplasia and prostate cancer.
Mhatre DR; Mahale SD; Khatkhatay MI; Desai SS; Jagtap DD; Dhabalia JV; Tongaonkar HB; Desai MP; Dandekar SP; Varadkar AM
Clin Chim Acta; 2014 Sep; 436():256-62. PubMed ID: 24952364
[TBL] [Abstract][Full Text] [Related]
16. Serum sialic acid and prostate-specific antigen in differential diagnosis of benign prostate hyperplasia and prostate cancer.
Romppanen J; Haapalainen T; Punnonen K; Penttilä I
Anticancer Res; 2002; 22(1A):415-20. PubMed ID: 12017325
[TBL] [Abstract][Full Text] [Related]
17. [Serum and urine prostate-specific antigen ratio: its value in the distinction between prostate cancer and adenoma when serum prostate-specific antigen level is between 4 and 10 ng/ml].
Irani J; Millet C; Levillain P; Doré B; Bégon F; Aubert J
Chirurgie; 1997; 122(8-9):478-82. PubMed ID: 9616891
[TBL] [Abstract][Full Text] [Related]
18. Differential diagnosis of prostate cancer and benign prostate hyperplasia using two-dimensional electrophoresis.
Charrier JP; Tournel C; Michel S; Comby S; Jolivet-Reynaud C; Passagot J; Dalbon P; Chautard D; Jolivet M
Electrophoresis; 2001 May; 22(9):1861-6. PubMed ID: 11425243
[TBL] [Abstract][Full Text] [Related]
19. An Automated Micro-Total Immunoassay System for Measuring Cancer-Associated α2,3-linked Sialyl N-Glycan-Carrying Prostate-Specific Antigen May Improve the Accuracy of Prostate Cancer Diagnosis.
Ishikawa T; Yoneyama T; Tobisawa Y; Hatakeyama S; Kurosawa T; Nakamura K; Narita S; Mitsuzuka K; Duivenvoorden W; Pinthus JH; Hashimoto Y; Koie T; Habuchi T; Arai Y; Ohyama C
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28241428
[TBL] [Abstract][Full Text] [Related]
20. A multicenter clinical trial on the use of alpha1-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis.
Lein M; Jung K; Hammerer P; Graefen M; Semjonow A; Stieber P; Ossendorf M; Luboldt HJ; Brux B; Stephan C; Schnorr D; Loening SA
Prostate; 2001 May; 47(2):77-84. PubMed ID: 11340629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
